Alpha Emitter Market, By Type of Radionuclide (Radium (Ra-223), Actinium (Ac-225), and Lead (Pb-212)), By Medical Applications (Prostate Cancer, Bone Metastases, Ovarian Cancer, Pancreatic Cancer, Endocrine Tumors, and Other Medical Applications), and By Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America)- Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030
Alpha emitters play a significant role in the treatment of different types of cancer. Targeted alpha therapy (TAT) is a therapeutic option in patients with multiple micro-metastases. Targeted alpha-particle therapy (or TAT) is an in-development method of targeted radionuclide therapy of various cancer. Properties of alpha emitters have led to exert profound differences between this field and other fields of nuclear medicine.
Market Dynamics:
Increase in burden of cancer, rise in geriatric population, increase in use of targeted alpha therapy (TAT) for cancer treatment, rise in awareness about the potential benefits of TAT, and increase in research and development are expected to propel the growth of the global alpha emitter market.
For instance, in July 2021, Alpha Tau Medical Ltd. and Healthcare Capital Corporation signed an agreement to further expand Alpha Tau's clinical strategy, including the pursuit of FDA (Food and Drug Administration) marketing authorization, a broad array of R&D (research and development) activities, expanding manufacturing capacity, and preparing for commercialization.
Key features of the study:
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook